By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Naxitamab > Naxitamab Side Effects
Miscellaneous antineoplastics

Naxitamab Side Effects

Applies to naxitamab: intravenous solution.

Warning

Intravenous route (Solution)

Warning: Serious Infusion-related Reactions and NeurotoxicitySerious Infusion-related Reactions: Naxitamab-gqgk can cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor. Premedicate prior to each naxitamab-gqgk infusion as recommended. Reduce the rate, interrupt infusion, or permanently discontinue naxitamab-gqgk based on severity.Neurotoxicity: Naxitamab-gqgk can cause severe neurotoxicity, including severe neuropathic pain, transverse myelitis, and reversible posterior leukoencephalopathy syndrome (RPLS). Premedicate to treat neuropathic pain as recommended. Permanently discontinue naxitamab-gqgk based on the adverse reaction and severity.

Serious side effects of Naxitamab

Along with its needed effects, naxitamab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking naxitamab:

More common

  • Back pain, sudden and severe
  • bigger, dilated, or enlarged pupils (black part of eye)
  • blurred vision
  • bone pain
  • burning, numbness, tingling, or painful sensations
  • change in color vision
  • chest tightness
  • confusion
  • decrease in frequency of urination
  • decrease in urine volume
  • difficulty in passing urine
  • difficulty seeing at night
  • dizziness
  • drowsiness
  • fever
  • flushing
  • headache
  • increased sensitivity of the eyes to light
  • muscle weakness, sudden and progressing
  • nausea and vomiting
  • nervousness
  • painful urination
  • pounding in the ears
  • seizures
  • slow or fast heartbeat
  • stomach pain
  • swelling
  • trouble breathing
  • unsteadiness or awkwardness
  • unusual tiredness or weakness
  • weakness in the arms, hands, legs, or feet

Less common

  • Constipation
  • diarrhea

Other side effects of Naxitamab

Some side effects of naxitamab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Blistering, peeling, loosening of the skin
  • chills
  • cough
  • decreased appetite
  • fast heartbeat
  • flushing, redness of the skin
  • increased sweating
  • itching
  • joint or muscle pain
  • red, irritated eyes
  • runny nose
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • unusual drowsiness, dullness, tiredness, weakness or feeling of sluggishness
  • unusually warm skin

For Healthcare Professionals

Applies to naxitamab: intravenous solution.

Hematologic

Very common (10% or more): Lymphocytes decreased (74%), platelet count decreased (65%), neutrophils decreased (61%), hemoglobin decreased (48%)[Ref]

Hypersensitivity

Very common (10% or more): Anaphylactic reaction (12%)[Ref]

Immunologic

Very common (10% or more): Influenza (12%)[Ref]

Local

Very common (10% or more): Infusion related reactions (e.g., hypotension, bronchospasm, flushing, wheezing, stridor, urticaria, dyspnea, pyrexia, infusion-related reaction, face edema, edema mouth, tongue edema, lip edema, respiratory tract edema, chills, hypoxia, pruritus, rash) (all Grades: 100%; Grade 3 or 4: 68%)[Ref]

Ocular

Very common (10% or more): Neurological disorders of the eye (e.g., unequal pupils, blurred vision, mydriasis) (24%)[Ref]

Metabolic

Very common (10% or more): Anorexia (53%), weight loss (12%)[Ref]

Psychiatric

Very common (10% or more): Anxiety (26%), irritability (25%)[Ref]

Respiratory

Very common (10% or more): Cough (60%), cough (57%), rhinorrhea (24%), breath sounds abnormal (15%), rhinovirus infection (12%), enterovirus infection (13%), upper respiratory tract infection (12%)[Ref]

Other

Very common (10% or more): Pain (e.g., pain, abdominal pain, pain in extremity, bone pain, neck pain, back pain, musculoskeletal pain) (all Grades: 100%; Grade 3 or 4: 72%), fatigue/asthenia (28%), pyrexia not occurring on the day of infusion or the day following an infusion (28%), contusion (15%)[Ref]

General

The most common adverse reactions were infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability. The most common Grade 3 or 4 laboratory abnormalities (5% or greater) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium, and decreased phosphate.[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (e.g., peripheral sensory neuropathy, paresthesia, neuralgia) (32%), headache (28%), depressed level of consciousness (24%), lethargy (14%)

Postmarketing reports: Transverse myelitis[Ref]

Cardiovascular

Very common (10% or more): Tachycardia/sinus tachycardia (84%), hypertension (all Grades: 44%; Grade 3 or 4: 4%), localized edema (25%)

Common (1% to 10%): Peripheral edema[Ref]

Dermatologic

Very common (10% or more): Erythema multiforme (33%), urticaria not occurring on the day of infusion or the day following an infusion (32%), hyperhidrosis (17%), erythema (11%)[Ref]

Gastrointestinal

Very common (10% or more): Vomiting (all Grades: 60%; Grade 3 or 4: 4%), diarrhea (all Grades: 56%; Grade 3 or 4: 8%), nausea (56%), constipation (15%), oropharyngeal pain (15%)[Ref]

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by